Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HK1 | P19367 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GALK1 | P51570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5636166 | 0.80 | NPC1 (0.55) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL1038154 | 0.75 | MAPT (0.41) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL6629250 | 0.71 | CA12 (0.45) | AHRPDK2HTR5AGAACYP1A2 | |
| SCHEMBL1816980 | 0.68 | AHR (0.63) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL29358826 | 0.67 | AHR (1.00) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL1144643 | 0.67 | AHR (1.00) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL19504 | 0.67 | AHR (1.00) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL6469101 | 0.67 | NPC1 (0.72) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL6630478 | 0.67 | ALDH1A1 (0.46) | AHRPDK2NPC1MAPTBRD4 | |
| SCHEMBL8872856 | 0.67 | CA12 (0.55) | AHRPDK2NPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1648 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113330001-B | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-07-02 | — | — | CN | claimed |
| US-20240132531-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2024-04-25 | — | — | US | claimed |
| EP-4326715-A1 | TRIAZOLONES, TETRAZOLONES, AND IMIDAZOLONES, OR THEIR SALTS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Yuhan Corporation (KR) | 2024-02-28 | — | — | EP | claimed |
| US-20240059728-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2024-02-22 | — | — | US | claimed |
| CN-117510350-A | Stilbene And-1 protein degradation agent, preparation method And application thereof | 中国医学科学院放射医学研究所 | 2024-02-06 | — | — | CN | claimed |
| CN-115515947-B | SHP2 inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| EP-4090660-B1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-31 | — | — | EP | claimed |
| CN-117203205-A | Triazolone, tetrazolone and imidazolone or salts thereof, and pharmaceutical compositions containing the same | 柳韩洋行 | 2023-12-08 | — | — | CN | claimed |
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-11-21 | — | — | US | claimed |
| CN-117043156-A | Novel galectin inhibitors of galectins | 格莱克特生物技术公司 | 2023-11-10 | — | — | CN | claimed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | claimed |
| EP-1299352-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-04-09 | — | — | EP | claimed |
| WO-2003002122-A1 | BETA-HYDROXYAMINE DERIVATIVES USEFUL IN TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-09 | — | — | WO | claimed |
| WO-2002094768-A2 | AZA HYDROXYLATED ETHYL AMINE COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2002-11-28 | — | — | WO | claimed |
| US-20020143177-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-10-03 | — | — | US | claimed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2002002506-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | claimed |
| WO-1997042168-A1 | THIO DERIVATIVES OF HYDROXAMIC ACIDS | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | VAPB, HDLBP, VAPA | AHR 3130/4885PDK2 2032/4885NPC1 11/4885 |
| US-20020143177-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, CHAT | AHR 814/4885PDK2 1324/4885NPC1 27/4885 |
| US-20240059728-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | AHR 2642/4885PDK2 2272/4885NPC1 1933/4885 |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | AHR 1619/4885PDK2 1582/4885NPC1 64/4885 |
| US-20240132531-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS3BP | AHR 2122/4885PDK2 1861/4885NPC1 3587/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | AHR 3324/4885PDK2 2387/4885NPC1 2366/4885 |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, CHAT | AHR 1502/4885PDK2 2677/4885NPC1 16/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | AHR 3239/4885PDK2 2836/4885NPC1 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.